6-hydroxy-1,2,3,4-tetrahydro-1-oxonaphthalene-2-acetic acid ethyl ester | 105806-38-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 6-hydroxy-1,2,3,4-tetrahydro-1-oxonaphthalene-2-acetic acid ethyl ester
• 英文别名: ethyl 2-(6-hydroxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetate；6-hydroxy-1,2,3,4-tetrahydro-1-oxo-2-naphthaleneacetic acid, ethyl ester；ethyl 2-(6-hydroxy-1-oxo-3,4-dihydro-2H-naphthalen-2-yl)acetate
• CAS: 105806-38-0
• 化学式: C₁₄H₁₆O₄
• 分子量: 248.279
• InChiKey: PJONVIXORDDEGG-UHFFFAOYSA-N

物化性质

• 沸点：
  423.6±38.0 °C(Predicted)
• 密度：
  1.209±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-hydroxy-1,2,3,4-tetrahydro-1-oxonaphthalene-2-acetic acid ethyl ester 生成 ethyl 2-[6-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-1-oxo-3,4-dihydro-2H-naphthalen-2-yl]acetate
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  6-甲氧基-1-萘满酮 在 甲烷磺酸 、 硫酸 、 水 、 氢溴酸 、 溶剂黄146 、 锌 作用下， 以 二乙二醇二甲醚 、 水 为溶剂， 反应 41.0h， 生成 6-hydroxy-1,2,3,4-tetrahydro-1-oxonaphthalene-2-acetic acid ethyl ester
  参考文献：
  名称：

  发现Tetralones作为酰基辅酶A：二酰基甘油酰基转移酶1的强效和选择性抑制剂

  摘要：

  酰基辅酶A：二酰基甘油酰基转移酶1（DGAT1）在甘油三酸酯合成中起重要作用，并且是治疗代谢性疾病的重要靶标。在这里，我们描述了新型DGAT1抑制剂四氢萘酮系列的结构-活性关系，以及我们克服化学结构中嵌入的苯胺的遗传毒性责任的策略，从而发现了候选化合物（S）-2-（6- （5-（3-（3,4-二氟苯基）脲基）吡嗪-2-基）-1-氧-2-（2,2,2-三氟乙基）-1,2,3,4-四氢萘-2-基）乙酸（GSK2973980A，26d）。化合物26d是一种有效的选择性DGAT1抑制剂，具有出色的DMPK谱和体内在小鼠餐后脂质漂移模型中的功效。基于在大鼠和狗中进行的为期7天的毒性研究中的总体生物学和可发育性特征以及可接受的安全性特征，化合物26d被选作候选化合物，用于进一步治疗代谢性疾病。

  DOI：

  10.1021/acsmedchemlett.7b00450

文献信息

• Novel Compounds as Diacylglycerol Acyltransferase Inhibitors
  申请人：CHRISTENSEN Rowena

  公开号：US20150307445A1

  公开（公告）日：2015-10-29

  This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.

  这项发明涉及一种新型化合物，它们是酰辅酶A：二酰基甘油酰基转移酶1（DGAT-1）的抑制剂，以及含有它们的药物组合物，它们的制备方法，以及它们在治疗中的应用，用于预防或治疗与DGAT-1功能障碍相关的疾病，或者调节DGAT-1活性可能具有治疗益处的疾病，包括但不限于肥胖、与肥胖相关的疾病、高三酸甘油酯血症、高脂蛋白血症、乳糜微粒血症、脂质代谢异常、非酒精性脂肪肝、糖尿病、胰岛素抵抗、代谢综合征、丙型肝炎病毒感染、痤疮或其他皮肤疾病。
• Leukotriene antagonists
  申请人：Eli Lilly and Company

  公开号：US04874777A1

  公开（公告）日：1989-10-17

  This invention provides benzene derivatives which are leukotriene antagonists, formulations of those derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.

  这项发明提供了苯基衍生物，这些衍生物是白三烯拮抗剂，以及这些衍生物的配方，以及使用这些衍生物治疗白三烯过度释放引起的疾病的方法。
• Vitronectin receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US20010034445A1

  公开（公告）日：2001-10-25

  Compounds of formula (I) are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis. 1

  式(I)的化合物被披露，它们是在治疗骨质疏松症中有用的维特龙蛋白受体拮抗剂。
• (Phenylmethoxy)phenyl derivatives of w-oxo- and w-tetrazolylalkanoic acids and related tetrazoles. Synthesis and evaluation as leukotriene D4 receptor antagonists
  作者：Robert D. Dillard、Richard A. Hahn、Doris McCullough、F. Patrick Carr、Lynn E. Rinkema、Carlos R. Roman、Jerome H. Fleisch

  DOI：10.1021/jm00113a014

  日期：1991.9

  Two series of (phenylmethoxy)phenyl compounds derived from the structure of LY163443 were synthesized and evaluated as leukotriene D4 receptor antagonists. In the OMEGA-[(phenylmethoxy)phenyl]-OMEGA-oxoalkanoic acid series, 5-[4-[(4-acetyl-2-ethyl-3-hydroxyphenyl)methoxy]phenyl]-3,3-dimethyl-5-oxopentanoic acid (8) was the most potent antagonist of LTD4-induced contractions of guinea pig ileum (pK(B) of 7.60) and LTD4 pressor response in pithed rats (ED50 of 1.4 mg/kg iv). Replacing the carboxylic acid function with 5-tetrazole gave slightly more potent compounds. In the OMEGA-[5-[[(phenylmethoxy)phenyl]alkyl]tetrazolyl]alkanoic acid series, replacing the carboxylic acid with 5-tetrazole gave compounds that were equally effective in the guinea pig ileum but more potent in vivo against the LTD4 pressor response in rat. The pK(B) value in the guinea pig ileum for 1-[2-hydroxy-3-propyl-4-[[4-[[2-[3-(1H-tetrazol-5-yl)propyl]-2H-tetrazol-5-yl]methyl]phenoxy]methyl]phenyl]ethanone (25) was 7.87 and the ED50 for antagonism of the LTD4 pressor response was 4.0 mg/kg iv. The sodium salts of 8 (9) and 25 (26) given by the iv route of administration antagonized LTD4-induced cardiovascular alterations in anesthetized rat and LTD4-induced bronchoconstriction in guinea pig in a dose-dependent manner. Oral activity was also demonstrated against the LTD4-induced bronchoconstriction in guinea pig.
• CARR, F. PATRICK;DILLARD, ROBERT D.;MCCULLOUGH, DORIS E.
  作者：CARR, F. PATRICK、DILLARD, ROBERT D.、MCCULLOUGH, DORIS E.

  DOI：——

  日期：——